Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with

Adolescent Adult Aged Allografts Disease-Free Survival Female Hematopoietic Stem Cell Transplantation Humans Leukemia, Myeloid, Acute / genetics Maintenance Chemotherapy Male Middle Aged Staurosporine / administration & dosage Survival Rate fms-Like Tyrosine Kinase 3 / genetics

Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
21 02 2019
Historique:
received: 13 08 2018
accepted: 24 11 2018
pubmed: 20 12 2018
medline: 24 10 2019
entrez: 20 12 2018
Statut: ppublish

Résumé

Patients with acute myeloid leukemia (AML) and a

Identifiants

DOI: 10.1182/blood-2018-08-869453 PMID: 30563875
pubmed: 30563875
pii: S0006-4971(20)42772-7
doi: 10.1182/blood-2018-08-869453
doi:

Substances chimiques

FLT3 protein, human EC 2.7.10.1
fms-Like Tyrosine Kinase 3 EC 2.7.10.1
Staurosporine H88EPA0A3N
midostaurin ID912S5VON

Banques de données

ClinicalTrials.gov
['NCT01477606']

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

840-851

Informations de copyright

© 2019 by The American Society of Hematology.

Auteurs

Richard F Schlenk (RF)

Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
National Center of Tumor Diseases-Trial Center, National Center of Tumor Diseases, German Cancer Research Center, Heidelberg, Germany.
Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
ORCID: 0000-0003-2215-2059

Daniela Weber (D)

Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.

Walter Fiedler (W)

Department of Internal Medicine II, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Helmut R Salih (HR)

Department of Hematology and Oncology, Eberhard-Karls University, Tübingen, Germany.

Gerald Wulf (G)

Department of Hematology and Oncology, University Hospital of Göttingen, Göttingen, Germany.

Hans Salwender (H)

Department of Oncology and Hematology, Asklepios Tumorzentrum, AK Altona, Hamburg, Germany.

Thomas Schroeder (T)

Department of Hematology, Oncology and Clinical Immunology, University of Duesseldorf, Medical Faculty, Duesseldorf, Germany.

Thomas Kindler (T)

Department of Hematology, Medical Oncology and Pneumology, University Medical Center, Mainz, Germany.

Michael Lübbert (M)

Department of Haematology-Oncology, Faculty of Medicine Freiburg, University of Freiburg Medical Center, Freiburg, Germany.

Dominik Wolf (D)

Internal Medicine III, University Hospital of Bonn, Bonn, Germany.

Jörg Westermann (J)

Department of Hematology, Oncology and Tumor Immunology, Charité-Campus Virchow Clinic, Berlin, Germany.

Doris Kraemer (D)

Department of Oncology and Hematology, Hospital Oldenburg, Oldenburg, Germany.

Katharina S Götze (KS)

Department of Internal Medicine III, University Hospital Klinikum rechts der Isar, Munich, Germany.
ORCID: 0000-0002-6276-8002

Heinz-August Horst (HA)

Department of Internal Medicine II, University Hospital of Schleswig-Holstein, Kiel, Germany.

Jürgen Krauter (J)

Department of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.

Michael Girschikofsky (M)

Department of Hematology and Oncology, Hospital Elisabethinen Linz, Linz, Austria.

Mark Ringhoffer (M)

Department of Hematology and Oncology, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany.

Thomas Südhoff (T)

Department of Hematology and Oncology, Klinikum Passau, Passau, Germany.

Gerhard Held (G)

Department of Internal Medicine I, University Hospital of Saarland, Homburg, Germany.

Hans-Günter Derigs (HG)

Department of Internal Medicine III, Hospital Frankfurt-Hoechst, Frankfurt, Germany.

Roland Schroers (R)

Department of Hematology and Oncology, Knappschaftskrankenhaus University Hospital, Bochum, Germany.

Richard Greil (R)

IIIrd Medical Department, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute, Cancer Cluster Salzburg, Salzburg, Austria.

Martin Grießhammer (M)

Department of Hematology and Oncology, University Hospital of Minden, Germany.

Elisabeth Lange (E)

Departmen of Hematology and Oncology, Evangelisches Krankenhaus Hamm, Hamm, Germany.

Alexander Burchardt (A)

Department of Hematology and Oncology, University Hospital of Gießen, Gießen, Germany.

Uwe Martens (U)

Department of Hematology and Oncology, Klinikum am Gesundbrunnen, Heilbronn, Germany.

Bernd Hertenstein (B)

Department of Hematology and Oncology, Klinikum Bremen Mitte, Bremen, Germany.

Lore Marretta (L)

Department of Hematology and Oncology, Vivantes Klinikum Neukölln, Neukölln-Berlin, Germany; and.

Michael Heuser (M)

Department of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.

Felicitas Thol (F)

Department of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.

Verena I Gaidzik (VI)

Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.

Wolfgang Herr (W)

Department of Hematology, Medical Oncology and Pneumology, University Medical Center, Mainz, Germany.

Julia Krzykalla (J)

Division of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg, Germany.

Axel Benner (A)

Division of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg, Germany.
ORCID: 0000-0002-7238-6956

Konstanze Döhner (K)

Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.

Arnold Ganser (A)

Department of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.

Peter Paschka (P)

Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.

Hartmut Döhner (H)

Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adolescent › Midostaurin added to chemotherapy and...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Midostaurin added to chemotherapy and...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Midostaurin added to chemotherapy and...
questionsmedicales.fr › Régions du corps › Transplants › Allogreffes › Midostaurin added to chemotherapy and...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Survie sans rechute › Midostaurin added to chemotherapy and...
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation cellulaire › Transplantation de cellules souches › Transplantation de cellules souches hématopoïétiques › Midostaurin added to chemotherapy and...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Midostaurin added to chemotherapy and...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Leucémies › Leucémie myéloïde › Leucémie aigüe myéloïde › Midostaurin added to chemotherapy and...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Chimiothérapie de maintenance › Midostaurin added to chemotherapy and...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Midostaurin added to chemotherapy and...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérocycliques 3 noyaux › Carbazoles › Staurosporine › Midostaurin added to chemotherapy and...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Mortalité › Taux de survie › Midostaurin added to chemotherapy and...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Tyrosine kinase-3 de type fms › Midostaurin added to chemotherapy and...